On July, 5 Analysts See $-0.32 EPS for Oramed Pharmaceuticals Inc. (ORMP)

June 27, 2018 - By Anthony Rauscher

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Corporate Logo
During 2018 Q1 the big money sentiment decreased to 0.33. That’s change of 2.42, from 2017Q4’s 2.75. 5 investors sold all, 4 reduced holdings as Oramed Pharmaceuticals Inc. ratio is negative. 1 grew holdings while 2 funds took holdings. Funds hold 234,885 shares thus 28.63% less from 2017Q4’s 329,110 shares.
2,600 were reported by Bancorp Of Montreal Can. Barclays Plc reported 0% of its capital in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Royal Retail Bank Of Canada has 1,500 shs. Pnc Finance Serv accumulated 0% or 21,200 shs. Tower Research Capital Ltd Company (Trc) holds 281 shs. Morgan Stanley holds 33,887 shs or 0% of its capital. Citigroup owns 6,545 shs for 0% of their capital. Architects Incorporated holds 2,750 shs. Glenmede Trust Company Na stated it has 20,000 shs. Deutsche Bank & Trust Ag owns 24,919 shs or 0% of their US capital. Retail Bank Of America Corp De accumulated 1,117 shs. Wells Fargo & Co Mn holds 0% or 8,100 shs in its capital. Moreover, Jfs Wealth Advsr Ltd Com has 0% invested in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Renaissance Technologies Ltd Com accumulated 69,800 shs.

Investors wait Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)’s quarterly earnings on July, 5., Faxor reports. Analysts forecast $-0.32 earnings per share, which is $0.17 down or 113.33 % from 2017’s $-0.15 earnings per share. Last quarter $-0.20 earnings per share was reported. Analysts predicts 60.00 % negative EPS growth this quarter. ORMP touched $7.47 during the last trading session after $0.02 change.Oramed Pharmaceuticals Inc. has volume of 15,010 shares. Since June 27, 2017 ORMP has declined 10.31% and is downtrending. ORMP underperformed the S&P 500 by 22.88%.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides.The firm is valued at $107.89 million. The Company’s product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes.Last it reported negative earnings. The firm operates primarily in Israel.

Another two news for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) were briefly announced by: Prnewswire.com on May 30, 2018 with title “Oramed Patent Allowed in the US for Oral Administration of Proteins”. The other Prnewswire.com‘s article was titled “Oramed to Present at the American Diabetes Association 78th Scientific Sessions” and announced on June 12, 2018.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.